Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Nintedanib, gefitinib, erlotinib, afatinib, osimertinib: Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration. Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells.

Study summary

The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer

Eligibility

Primary outcome measure(s)

• The toxicity of combinate nintedanib and EGFR TKI — Assessed every 6 weeks of chest CT scan until PD.
• Patient objective response rate — Assessed every 6 weeks of chest CT scan

Trial sites (1)

More China Medical University Hospital trials in Taiwan

Other trials for the same condition